New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 27, 2012
05:12 EDTREGNRegeneron's Eylea Injection approved by European Commission
Regeneron Pharmaceuticals announced that Eylea Injection has been approved by the European Commission for the treatment of patients with neovascular, or wet, age-related macular degeneration, also known as wet AMD. According to the European Medicines Agency, or EMA, approved Summary of Product Characteristics, Eylea treatment is initiated with one 2 mg injection per month for three consecutive months, followed by one injection every two months. There is no requirement for monitoring by the physician between injections. After the first twelve months of treatment with Eylea, the treatment interval may be extended based on visual and anatomic outcomes. In such cases, the frequency of monitoring visits is determined by the treating physician and may be more often than the schedule of injections.
News For REGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 2, 2015
07:49 EDTREGNRegeneron Eylea data positive, says RBC Capital
Subscribe for More Information
February 24, 2015
07:31 EDTREGNRBC Capital to hold a conference
Subscribe for More Information
February 20, 2015
16:48 EDTREGNDow, S&P 500 finish week at record highs after Greek deal reached
Subscribe for More Information
12:07 EDTREGNEYLEA reimbursment could be influenced by UK recommendation, says Piper Jaffray
Subscribe for More Information
12:01 EDTREGNNICE recommends EYLEA for DME, but only in certain cases
Subscribe for More Information
07:08 EDTREGNAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
16:28 EDTREGNOn The Fly: Closing Wrap
Subscribe for More Information
15:58 EDTREGNRegeneron downgraded to Neutral from Buy at Roth Capital
Subscribe for More Information
10:00 EDTREGNRegeneron Praluent launch costs a concern, says Piper Jaffray
Subscribe for More Information
09:01 EDTREGNData to accelerate growth of Regeneron's Eylea, says Bernstein
Subscribe for More Information
07:28 EDTREGNRegeneron data better than expected, says RBC Capital
RBC Capital believes that Protocol-T results for Regneron's (REGN) Eylea were better than expected. The firm says that Eylea improved the vision of all patients more than Roche's treatments,and was much better than Roche's drugs in treating patients with moderate or worse vision loss. The firm keeps a $490 price target and Outperform rating on Regeneron.
06:56 EDTREGNData support Regeneron drug over competition, says Deutsche Bank
Subscribe for More Information
06:45 EDTREGNStudy shows Roche's treatments equal to Eylea in most cases, NY Times says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use